<DOC>
	<DOCNO>NCT00242424</DOCNO>
	<brief_summary>Study safety immunogenicity ( antibody produce capability ) comparing inactivated influenza vaccine placebo give infant 2 3 month age . Infants receive inactivate influenza vaccine time vaccine routine immunization schedule . Infants randomize enrollment receive inactivate influenza vaccine placebo 2:1 ratio . This study double-blind , randomize , placebo-controlled .</brief_summary>
	<brief_title>Safety Immunogenicity Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks Age</brief_title>
	<detailed_description>Methods : A double-blind , randomize , placebo-controlled trial conducted 1375 healthy US infant 6-12 week age . Subjects receive either 2 dos trivalent inactivated influenza vaccine ( TIV , Fluzone® , sanofi pasteur 2005-6 pediatric formulation ) ( N=915 ) placebo ( N=460 ) 1 month apart , along indicate concomitant vaccine . Solicited adverse event collect 7 day follow vaccination , unsolicited adverse event 28 day , serious adverse event 6 month . Hemagglutination inhibition antibody 3 vaccine strain measure follow second TIV/placebo dose . Results : No significant difference see TIV placebo group safety outcome . Fever ≥38oC rectal within 3 day vaccination see 11.2 % vs 11.7 % TIV v placebo recipient . Serious adverse event within 28 day vaccine/placebo report 1.9 % TIV 1.5 % placebo recipient ; one ( hypersensitivity reaction TIV recipient ) consider vaccine-related . Significantly increase antibody response ( p &lt; 0.001 ) see 3 strain TIV recipient titer ≥ 1:40 geometric mean titer ( GMT ) ( p &lt; 0.001 ) . Altogether , 50 % infant antibody titer ≥ 1:40 H1N1 , 86 % H3N2 , 11 % B compare 7 % , 10 % , 0.3 % placebo group . The reciprocal GMT influenza recipient 33 , 95 , 11 H1N1 , H3N2 , B vs. 7 , 9 , 5 placebo recipient . Over 90 % infant receive TIV antibody ≥ 1:40 least one vaccine strain 49.6 % 2 strain , vs. 16.4 % 0.9 % placebo group . Conclusions : TIV administer young infant begin 6-12 week age safe immunogenic .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age 42 84 day day inclusion Full term ( born &gt; =36 week birth weight &gt; =2.5 kg Considered good health Parental consent obtain available Available study duration ( 6 month ) Reported allergy egg protein , chicken proteins Previous history influenza vaccination disease Receipt vaccine Hepatitis B prior enrollment Acute illness rectal temperature &gt; = 38.0 ( defer enrollment ) Known bleed disorder Participation interventional clinical trial within 30 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>84 Days</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>influenza vaccine</keyword>
	<keyword>infant</keyword>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
</DOC>